Review
Hematology
Max J. Gordon, Mitchell R. Smith, Loretta J. Nastoupil
Summary: This article reviews the development and treatment of follicular lymphoma, including the molecular concepts and classification, chemotherapy and monoclonal antibodies targeting CD20. It also highlights the research progress in understanding the pathophysiology of follicular lymphoma and developing targeted therapies over the past decade, as well as new immunotherapeutic strategies for B-cell lymphomas, particularly advanced stage patients. These studies bring hope for the treatment of follicular lymphoma.
Review
Hematology
Emil Kumar, Lucy Pickard, Jessica Okosun
Summary: Follicular lymphoma (FL) is a heterogeneous disease with increasing recognition of recurrent genetic alterations in epigenetic regulators as a pivotal hallmark. Studies are beginning to uncover the convergence between genetics, epigenetics, and the tumor microenvironment, emphasizing the need to integrate biology with therapeutics for optimal patient care.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Review
Pharmacology & Pharmacy
Michael Northend, William Townsend
Summary: Follicular lymphoma is the most common form of indolent non-Hodgkin lymphoma, with a long median overall survival and high response rates to current therapies. Some patients show aggressive behavior or resistance to treatment, leading to poor outcomes, but new therapies like lenalidomide and immunotherapies are offering hope for the future.
Editorial Material
Gastroenterology & Hepatology
Takuya Watanabe
Summary: Primary follicular lymphoma (FL) of the gastrointestinal tract is increasingly detected in Japan, with good prognosis in many cases. However, in Europe and the United States, gastrointestinal FL is more commonly found in advanced cases. This editorial provides an overview of recent therapeutic advances in nodal FL and discusses the future possibilities for treating gastrointestinal FL, especially in advanced cases.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)
Review
Dermatology
Barbara Ma, Niroshana Anandasabapathy
Summary: Immune checkpoint blockade has revolutionized the treatment of various tumors, but it can lead to immune-related adverse events (irAEs) in the skin. This article reviews the reasons for using immune checkpoint blockade, current drugs, their applications in skin cancers, autoimmune manifestations in the skin, and the lack of preclinical modeling in this area.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2022)
Article
Immunology
Juan Liu, Xiaomin Zhang, Xuetao Cao
Summary: This review discusses the activation and functional changes of dendritic cells (DCs) during the development of systemic lupus erythematosus (SLE) and explores the therapeutic potential of targeting DCs in the treatment of SLE.
JOURNAL OF AUTOIMMUNITY
(2022)
Review
Immunology
Amber G. Bozward, Vincenzo Ronca, Daniel Osei-Bordom, Ye Htun Oo
Summary: The close relationship between the gastrointestinal tract and liver constitutes the gut-liver axis, playing a central role in the pathogenesis of gut-liver axis diseases. This axis is crucial for immune homeostasis, influenced by factors such as the gut microbiota, diet, genetics, and environment. Through the coordinated effort of immune cells network, the liver is able to maintain its tolerogenic state.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Xingfang Xiong, Xiaoli Xie, Yu Zhang, Lijuan Wang
Summary: Lymphoma is a common malignant blood tumor originating from lymph nodes or other lymphoid tissues. Tumor-associated macrophages (TAMs), particularly M2-like TAMs, have a significant impact on lymphoma growth and patient prognosis. Understanding the origin, function, and mechanism of TAMs in lymphoma can help identify potential therapeutic targets and treatment strategies.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Tianyuan Xu, Zhong Zheng, Weili Zhao
Summary: Follicular lymphoma (FL) is a heterogeneous lymphoma originating from germinal center B cells. Multi-omics analysis has revealed abnormalities in FL cells and tumor microenvironment, providing insights into the mechanisms of FL progression and potential therapeutic options.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Salvatrice Mancuso, Marta Mattana, Melania Carlisi, Marco Santoro, Sergio Siragusa
Summary: B-cell lymphoma and lymphoproliferative diseases are a heterogeneous group of neoplasms accompanied by immune regulatory disorders. Immunological imbalance plays an important role in the development and progression of lymphoma. Modulating the immune system can have a profound impact on disease progression or resolution, making it a critical target for new therapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Health Care Sciences & Services
Karthik Nath, Maher K. Gandhi
Summary: Follicular lymphoma, the most common indolent B-cell lymphoma, has different prognoses, but the emergence of novel targeted agents offers hope for future treatment options.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Review
Immunology
Yue Lang, Yanan Lyu, Yehui Tan, Zheng Hu
Summary: Hematological malignancy is a serious disease that endangers human health and the research on its pathogenesis and therapies relies on the use of animal models. Recent studies have increasingly utilized mouse models hosting human hematological malignancy, which can better mimic human characteristics. Depending on the construction methods, these models can be categorized into different types with diverse characteristics and application values. Various strategies have also been developed to improve the engraftment and differentiation of human hematological malignant cells in vivo. Additionally, the humanized mouse model with both functional human immune system and autologous human hematological malignancy provides a unique tool for evaluating the efficacy of novel immunotherapeutic drugs/approaches.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Luana Tripodi, Chiara Villa, Davide Molinaro, Yvan Torrente, Andrea Farini
Summary: The interaction between the immune system and skeletal muscle plays a crucial role in inflammatory muscle diseases and dystrophic conditions, affecting muscle regeneration and pathogenesis.
Review
Oncology
James A. Fagin, Gnana P. Krishnamoorthy, Inigo Landa
Summary: This review outlines the genomic simplicity of differentiated cancers derived from thyroid follicular cells and explores the impact of oncogenic drivers on tumor phenotypes. The activation of key nodes in the receptor tyrosine kinase-RAS-BRAF pathway by oncoproteins in thyroid cancer leads to constitutive MAPK signaling with varying degrees of activity based on their specific biochemical mechanisms. The magnitude of MAPK signaling determines important aspects of thyroid cancer biology, including differentiation state, invasiveness, and tumor microenvironment. Genomic lesions, chromatin accessibility disruption, cell cycle dysfunction, and progressive immunosuppression in the tumor microenvironment contribute to disease progression.
NATURE REVIEWS CANCER
(2023)
Editorial Material
Hematology
James D. Phelan, Elaine S. Jaffe
Summary: In this study, the authors used whole genome sequencing to investigate the basis of follicular lymphoma (FL) transformation. They identified two genetically distinct subgroups of FL, dFL and cFL, which showed a significant difference in time to transformation.
Article
Oncology
Matthew D. Blunt, Stefan Koehrer, Rachel C. Dobson, Marta Larrayoz, Sarah Wilmore, Alice Hayman, Jack Parnell, Lindsay D. Smith, Andrew Davies, Peter W. M. Johnson, Pamela B. Conley, Anjali Pandey, Jonathan C. Strefford, Freda K. Stevenson, Graham Packham, Francesco Forconi, Greg P. Coffey, Jan A. Burger, Andrew J. Steele
CLINICAL CANCER RESEARCH
(2017)
Article
Oncology
S. Drennan, A. D'Avola, Y. Gao, C. Weigel, E. Chrysostomou, A. J. Steele, T. Zenz, C. Plass, P. W. Johnson, A. P. Williams, G. Packham, F. K. Stevenson, C. C. Oakes, F. Forconi
Article
Medicine, General & Internal
P. Ghia, B. Nadel, B. Sander, K. Stamatopoulos, F. K. Stevenson
JOURNAL OF INTERNAL MEDICINE
(2017)
Review
Hematology
Ralf Kueppers, Freda K. Stevenson
Article
Oncology
Alex Allen, Chuan Wang, Lisa J. Caproni, Gessa Sugiyarto, Elena Harden, Leon R. Douglas, Patrick J. Duriez, Kinga Karbowniczek, Jon Extance, Paul J. Rothwell, Ifeayinwa Orefo, John P. Tite, Freda K. Stevenson, Christian H. Ottensmeier, Natalia Savelyeva
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2018)
Article
Oncology
Samantha Drennan, Giorgia Chiodin, Annalisa D'Avola, Ian Tracy, Peter W. Johnson, Livio Trentin, Andrew J. Steele, Graham Packham, Freda K. Stevenson, Francesco Forconi
CLINICAL CANCER RESEARCH
(2019)
Letter
Oncology
Lindsay D. Smith, Annabel R. Minton, Matthew D. Blunt, Laura I. Karydis, David A. Dutton, Karly-Rai Rogers-Broadway, Rachel Dobson, Rena Liu, Faith Norster, Elizabeth Hogg, Margaret Ashton-Key, Jonathan C. Strefford, Li Jia, Dimitar G. Efremov, G. Vignir Helgason, Peter W. M. Johnson, Freda K. Stevenson, Francesco Forconi, Mark S. Cragg, David A. Tumbarello, Graham Packham, Andrew J. Steele
Article
Hematology
Mariette Odabashian, Emanuela Carlotti, Shamzah Araf, Jessica Okosun, Filomena Spada, John G. Gribben, Francesco Forconi, Freda K. Stevenson, Mariarita Calaminici, Sergey Krysov
Article
Oncology
Elizabeth A. Lemm, Beatriz Valle-Argos, Lindsay D. Smith, Johanna Richter, Yohannes Gebreselassie, Matthew J. Carter, Jana Karolova, Michael Svaton, Karel Helman, Nicola J. Weston-Bell, Laura Karydis, Chris T. Williamson, Georg Lenz, Jeremy Pettigrew, Curtis Harwig, Freda K. Stevenson, Mark Cragg, Francesco Forconi, Andrew J. Steele, Jennifer Cross, Lloyd Mackenzie, Pavel Klener, Graham Packham
CLINICAL CANCER RESEARCH
(2020)
Article
Hematology
Giorgia Chiodin, Joel D. Allen, Dean J. Bryant, Philip Rock, Enrica A. Martino, Beatriz Valle-Argos, Patrick J. Duriez, Yasunori Watanabe, Isla Henderson, James S. Blachly, Katy J. McCann, Jonathan C. Strefford, Graham Packham, Teunis B. H. Geijtenbeek, Carl G. Figdor, George W. Wright, Louis M. Staudt, Richard Burack, Thomas A. Bowden, Max Crispin, Freda K. Stevenson, Francesco Forconi
Summary: The glycosylation of the Ig variable region is a rare feature associated with follicular lymphoma, and some DLBCLs acquire N-glycosylation sites selectively in the CDRs of the antigen-binding sites, particularly in the EZB subtype; this contrasts with the activated B-cell-like DLBCL Ig. The acquisition of these sites is associated with mutations of epigenetic regulators and BCL2 translocations, and the oligomannosylated tumor Ig can be a potential therapeutic target against DC-SIGN-expressing M2-polarized macrophages.
Article
Hematology
Freda K. Stevenson, Francesco Forconi, Thomas J. Kipps
Summary: Research into chronic lymphocytic leukemia has led to significant improvements in the assessment and treatment of patients, with designer drugs now successfully targeting tumor cells based on their biology. Classifying CLL into unmutated (U) and mutated (M) diseases based on the mutational status of IGHV sequences reveals distinct origins, biology, and clinical behaviors for each. Despite advances, challenges such as cell-escape strategies and immunosuppression remain, necessitating continued research into CLL biology.
Article
Multidisciplinary Sciences
Beatriz Valle-Argos, Giorgia Chiodin, Dean J. Bryant, Joe Taylor, Elizabeth Lemm, Patrick J. Duriez, Philip J. Rock, Jonathan C. Strefford, Francesco Forconi, Richard W. Burack, Graham Packham, Freda K. Stevenson
Summary: In follicular lymphoma, lectin DC-SIGN modulates the function of sIg by binding to acquired mannoses, triggering cell signaling pathways similar to anti-IgM, activating pathways associated with B-cell survival, proliferation and cell-cell communication. This alternative engagement of the B-cell receptor provides lymphoma cells with activation of signaling responses and protection from exogenous antigens.
SCIENTIFIC REPORTS
(2021)
Article
Hematology
Giorgia Chiodin, Samantha Drennan, Enrica A. Martino, Laura Ondrisova, Isla Henderson, Luis del Rio, Ian Tracy, Annalisa D'Avola, Helen Parker, Silvia Bonfiglio, Lydia Scarfo, Lesley-Ann Sutton, Jonathan C. Strefford, Jade Forster, Oliver Brake, Kathleen N. Potter, Benjamin Sale, Stuart Lanham, Marek Mraz, Paolo Ghia, Freda K. Stevenson, Francesco Forconi
Summary: Chronic lymphocytic leukemia (CLL) cells with high surface IgM (sIgM) levels progress more rapidly and can regain sIgM expression during ibrutinib therapy. High sIgM levels are associated with shorter time to new treatment. Ibrutinib inhibits sIgM-mediated signaling more effectively in CLL cells with low sIgM levels.
Article
Cell Biology
Rachael Arthur, Alexander Wathen, A. Elizabeth Lemm, K. Freda Stevenson, Francesco Forconi, J. Adam Linley, J. Andrew Steele, Graham Packham, Beatriz Valle-Argos
Summary: BTK inhibitors (BTKi) have shown significant improvement in the treatment of chronic lymphocytic leukemia (CLL) and certain forms of B-cell lymphoma. However, the activation of BTK-independent calcium signaling may limit the efficacy of BTKi. Inhibition of SYK or dual inhibition of BTK and RAC may be alternative strategies to enhance pathway blockade.
CELLULAR SIGNALLING
(2022)
Article
Oncology
Dean Bryant, Lindsay Smith, Karly Rai Rogers-Broadway, Laura Karydis, Jeongmin Woo, Matthew D. Blunt, Francesco Forconi, Freda K. Stevenson, Christopher Goodnow, Amanda Russell, Peter Humburg, Graham Packham, Andrew J. Steele, Jonathan C. Strefford
Summary: Chronic lymphocytic leukaemia (CLL) cells can express unmutated (U-CLL) or mutated (M-CLL) immunoglobulin heavy chain (IGHV) genes, with differences in clinical behaviors, B cell receptor (BCR) signaling capacity, and transcriptional profiles. Through mRNA/miRNA sequencing of 38 CLL cases, researchers identified differentially expressed mRNAs and miRNAs between U-CLL and M-CLL, as well as potential regulatory roles of the 14q32 miRNA locus in CLL-related gene regulation and BCR signaling.